Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Celsion And Yakult Honsha Announce Start-up Of Japanese Clinical Trial Sites In Celsion's Global Phase III ThermoDox(R) Trial For Primary Liver Cancer
Celsion Corporation (NASDAQ: CLSN) and Yakult Honsha Co., Ltd. (Tokyo: 2267) announced that Celsion"s global Phase III ThermoDox trial for the treatment of primary liver cancer will be extended to Japan by Yakult"s expertise. This is an important step towards a potential application to market the drug in Japan. Yakult Honsha is the exclusive licensor of Celsion"s ThermoDox in Japan.
generic viagra online
Mental Health Patients Neglected And Forgotten, UK
-39% of suicides by hanging took place when the patient was supposed to be subject to observation by staff
News of the day
States To Pursue New Integrated Care Approaches For Dual Eligibles
As the nation debates health reform options, the Center for Health Care Strategies (CHCS) is launching Transforming Care for Dual Eligibles , a state initiative to test innovative care models for people who are dually eligible for Medicare and Medicaid ("dual eligibles"). Colorado, Maryland, Massachusetts, Michigan, Pennsylvania, Texas, and Vermont will implement strategies to improve care and control costs for dual eligibles, a high-need population with health care costs nearly five times those of other Medicare beneficiaries. The program is made possible through support from The Commonwealth Fund.
Nutrition

Cambridge Consultants To Showcase Inhaler Design And Development Process At RDD 2009, Europe

Cambridge Consultants will be showcasing its proprietary design and development process for Dry Power Inhalers (DPIs) at the Respiratory Drug Delivery (RDD) Europe 2009 conference in Lisbon later this month.÷  The company will demonstrate its ability to move inhaler design quickly through all stages of development from concept through manufacture to final product, getting it right first time, accelerating the creation of new inhalable drug delivery devices, and offering pharmaceutical companies a quick route to market, saving up to six months in development. "Our RDD presence is all about the importance of speed to market, and this demonstration is designed to highlight the range of development capabilities we can deploy to achieve it for our clients," commented David Blakey, Head of Drug Delivery at Cambridge Consultants.÷  "It is crucial to ensure process quality in stages such as concept creation, complex mathematical modelling and detailed design.÷  These are areas where Cambridge Consultants adds significant value, based on our skill and experience in running turn key developments, from concept to clinical trial and through transfer to manufacture." Cambridge Consultants will be using Gen-X, a proprietary DPI, to demonstrate the key stages in the design cycle.÷  The display tracks the stages of the process up to the test bed stage, where the efficacy of the de-aggregation engine has been tested.÷  Cambridge Consultants is currently selecting development partners to take this concept to market. David Blakey adds: "Supported by our proprietary design and development process, our partners can cut up to six months off the development cycle for DPIs, giving them a significant head start and reducing development risk." The demonstration of Cambridge Consultants" product development process will be available on Cambridge Consultants" stand at the Respiratory Drug Delivery Europe 2009 conference in Lisbon, Portugal, from 19-22 May. Cambridge Consultants


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009